Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
  • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
  • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
  • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
  • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
  • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
  • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
  • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2603/00—Systems containing at least three condensed rings
  • C07C2603/02—Ortho- or ortho- and peri-condensed systems
  • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
  • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
  • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
  • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
  • C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Definitions

• the present invention provides a method for the purification of prostaglandins.
• the present invention provides a method for the purification of prostaglandins by supercritical fluid chromatography (SFC).
• SFC supercritical fluid chromatography
• Prostaglandins are active pharmaceutical ingredients (APIs) and isomerically and chemically pure prostaglandins are required for formulation into drug products.
• the present invention provides a method for the purification of a
• the invention includes a method for purifying a crude prostaglandin, comprising injecting the crude prostaglandin onto a column comprising a stationary phase, eluting the crude prostaglandin through the column using a mobile phase comprising
• Figure 1 illustrates a chromatogram of a SFC purification injection of crude latanoprost, obtained as described in Example 1.
• Figure 2 sets out the structures of latanoprost isomers.
• Figure 3 illustrates a chromatogram of a SFC purification injection of crude latanoprost, obtained as described in Example 2.
• purification it is meant the method produces a prostaglandin which is chemically and/or isome ⁇ cally pure.
• a chemically pure compound is one where the compound is essentially free from related compounds, chemical starting materials, chemical intermediates and chemical degradants.
• An isome ⁇ cally pure compound is one where the compound is essentially free from known related compounds of the same chemical molecular formula that are different in chemical structure.
• the purified prostaglandin is at least about 99% chemically pure, preferably at least about 99.5% chemically pure and more preferably at least about 99.8% chemically pure.
• the purified prostaglandin is at least 99% isomerically pure, preferably at least about 99.5% isomerically pure and more preferably at least about 99.9% isomerically pure.
• the method of the present invention may be utilised to purify a prostaglandin on an analytical or preparative scale.
• analytical we mean a scale of providing at least about O. lmg of purified prostaglandin, preferably about lmg of purified prostaglandin, in a reasonable timeframe, i.e. less than a day.
• preparative we mean a scale of providing at least about lmg of purified prostaglandin, preferably about O. lg of purified prostaglandin and most preferably about Ig of purified prostaglandin, in a reasonable timeframe, i.e. less than a day.
• the prostaglandin is a compound of formula (I), a compound of formula (II), a compound of formula (III) or a compound of formula (IV) :
• X is CONR 12 Ri 3 or CO 2 Ri 2 :
• Z is Ci 2 o-alkyl, C 2 20 -alkynyl, -0-(C 5 2 o-aryl) or -(Ci 2 o-alkyl)-(C 6 20 -aryl), wherein the aryl group is optionally substituted with one to three substituents selected from the group consisting of Ci 20 -alkyl, halo and C(halo) 3 ;
• Ri and R 2 are independently H or OH, or R 1 and R 2 together form ⁇ ;
• R 3 and R 4 are independently H or OH
• R 5 and R 5 are independently H or OH, or R 5 and R 5 together form ⁇ ,
• R 7 and R 8 are independently H, OH, halo or C 1 20 -alkyl
• Rg and Ri 0 are independently H or C 1 20 -alkyl, wherein the alkyl group is optionally substituted with one or more substituents selected from CONR 12 R 13 , CO 2 Ri 2 or CO 2 M + ;
• R 11 is Ci 20 -alkyl or -0-(C 1 20 -alkyl), wherein the alkyl group is optionally substituted with one or more substituents selected from CONRi 2 Ri 3 , CO 2 Ri 2 or CO 2 M + ;
• Ri 2 and R i3 are independently selected from the group consisting of H and Ci 20 alkyl; M + is a counter cation; and
• Halo is fluorine, chlorine, bromine or iodine.
• Alkyl refers to linear, branched or cyclic saturated hydrocarbon structures having, unless otherwise indicated, 1 to 20 carbon atoms, more preferably 1 to 15 carbon atoms and most preferably 1 to 10 carbon atoms.
• alkyl groups are methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, i-butyl, t-butyl, n-pentyl, n-hexyl and cyclohexyl.
• alkyl group having a specific number of carbons atoms is named, it is intended that all geometric isomers of that alkyl group are encompassed.
• butyl includes n-butyl, t-butyl, t-butyl and cyclobutyl.
• Alkynyl refers to linear or branched hydrocarbon structures having at least one
• alkynyl groups are ethynyl, propynyl, n-butynyl, isobutynyl and hexynyl.
• alkynyl group having a specific number of carbon atoms it is intended that all geometric isomers of that aikyny! group are encompassed.
• butyrsy! includes n- butynyl and isobutynyl.
• Aryl refers to an aromatic hydrocarbon structure having, unless otherwise indicated, 6 to 20 carbon atoms, more preferably 6 to 15 carbon atoms and most preferably 6 to 10 carbon atoms. Examples of aryl groups are phenyl and naphthyl.
• halo whether alone or as part of another group refers to a halogen, for example, a fluorine, chlorine, bromine or iodine atom.
• M + is a counter cation of -CO 2 i.e -CO 2
• M + is a carboxylic acid salt and preferably a pharmaceutically acceptable carboxylic acid salt.
• M + is a metal ion e.g. an alkali metal ion, such as K + or Na + .
• X is preferably CONH(C 1 10 -alkyl), CO 2 (C 1 10 -alkyl) or CO 2 H. More preferably, X is selected from the group consisting of CONHEt, CO 2 Me, CO 2 1 Pr and CO 2 H.
• Z is C 1 10 -alkyl, C 2 10 -alkynyl, -0-(C 6 10 -aryl) or -(C-, 10 -alkyl)-(C ⁇ 10 -aryl), wherein the aryl group is optionally substituted with one to three substituents selected from the group consisting of Cl and -CF 3 . More preferably, Z is -(CH 2 ) 5 CH 3 , -(CH 2 ) 3 CH 3 , -CH 2 -Ph, 1 Ri and R 2 may independently be H or OH. Preferably, when one of R 1 and R 2 is H, the other of R 1 and R 2 is OH. More preferably, when one of R 1 and R 2 is H and the other of Ri and R 2 is OH, R 1 , R 2 and the carbon atom to which they are attached have the following stereochemistry:
• R 3 and R 4 are independently H or OH.
• R 3 and R 4 are independently H or OH.
• R 3 , R 4 and the carbon atom to which they are attached have the following stereochemistry: V V
• R 5 and R 6 may independently be H or OH. In one embodiment, when one of R 5 and R 6 is H, the other of R 5 and R 6 is OH. More preferably, when one of R 5 and R 6 is H and the other of R 5 and R 6 is OH, R 5 , R 5 and the carbon atom to which they are attached have the following stereochemistry:
• R 5 and R 6 are both H.
• R 7 and R 8 are independently selected from the group consisting of H, OH, F or CH 3 .
• R 7 and R 8 are both H.
• R 7 and R 8 are both F
• one of R 7 and R 8 is CH 3 and the other of R 7 and R 8 is H or OH.
• R 9 and R 10 are independently H or Ci i O -alkyl, wherein the alkyl group is optionally substituted with one or more substituents selected from CO 2 H or CO 2 M + . More preferably, one of R 9 and R 10 is H and the other of R 9 and R 10 is -(CH 2 ) 3 CO 2 H or - (CHz) 3 CO 2 Na + .
• Rn is Ci i O -alkyl or -0-(Ci l o-alkyl), wherein the alkyl group is optionally substituted with one or more substituents selected from CO 2 H or CO 2 M + . More preferably, R 11 is -(CH 2 ) 3 CO 2 H or -0-CH 2 -CO 2 H.
• the prostaglandin is selected from the group consisting of:
• the prostaglandin is latanoprost.
• the prostaglandin can be luprostiol:
• the stationary phase is a chiral stationary phase.
• the chiral stationary phase is a de ⁇ vatised amylose or cellulose polymer or other
• the chiral stationary phase is selected from the group consisting of Chiralcel OD-H, ChiralPak AS-H, ChiralPak IC, ChiralPak AD-H, Chiralcel OJ-H and Chiralcel OK (products available from Chiral Technologies Inc. and Daicel Chemical Industries, Ltd .). More preferably, the chiral stationary phase is ChiralPak AD-H.
• the amylase or cellulose polymer may be de ⁇ vatised with one or more carbamate groups, especially aryl- containing carbamate groups such as 3,5-d ⁇ methylphenylcarbamate, (S)-alpha- methylbenzylcarbamate, 4-chlorophenyl carbamate, 4-methylphenylcarbamate, phenyl carbamate, 3-chloro-4-methylphenylcarbamate, 5-chloro-2-methylphenylcarbamate or the like, and/or one or more ester groups, such as acetate, benzoate (e.g., 4-methyl benzoate), cinnamate, or the like.
• carbamate groups especially aryl- containing carbamate groups such as 3,5-d ⁇ methylphenylcarbamate, (S)-alpha- methylbenzylcarbamate, 4-chlorophenyl carbamate, 4-methylphenylcarbamate, phenyl carbamate, 3-chloro-4-methylphenylcarbamate,
• the stationary phase is a non-chiral stationary phase.
• the non-chiral stationary phase is selected from the group consisting of Princeton Diol, 4-ethyl pyridine, 2-ethyl pyridine and pyridine urea.
• the mobile phase further comprises at least one modifier.
• the modifier can be any suitable liquid solvent.
• a suitable modifier may be selected from the group consisting of at least one alcohol, acetonitrile, ethyl acetate, methylene chloride and a combination thereof.
• the at least one alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol and a combination thereof. It is desirable that the modifier is compatible with the stationary phase. For example, ethyl acetate and methylene chloride cannot be used with a ChiralPak AD column as they will destroy the column.
• the purified prostaglandin can be provided as a solution with the modifier as a solvent. It may therefore be desirable to select a modifier in which the prostaglandin is soluble.
• the at least one modifier is present in a quantity from (i.e., of at least) about 1% v/v or about 1% w/w to the supercritical carbon dioxide. More preferably, the at least one modifier is present in a quantity from (i.e., of at least) about 5% v/v or about 5% w/w to the supercritical carbon dioxide.
• the ratio of modifier to carbon dioxide can be varied during the chromatographic process.
• Suitable chromatographic apparatus is well known to the skilled person. It is preferred to use an apparatus that is suitable for Supercritical Fluid Chromatography such as the Thar Investigator SFC or Novasep Supersep 20/30 SFC.
• the crude feed containing the crude prostaglandin is periodically injected into the apparatus wherein the mobile phase flows through the stationary phase which is located in a column. After detection at the column outlet, the purified fractions of the feed are directed to different traps The carbon dioxide is removed from the purified fractions and is preferably recycled
• Detection at the column outlet can be conducted by measuring UV absorption at an appropriate wavelength.
• the column diameter is suitably from about 2mm to about 7mm, preferably about 4.6mm .
• the column length is suitably from about 5cm to about 50cm, preferably about 25cm.
• the column diameter is suitably from about 10mm to about 200mm, preferably about 21mm.
• the column length is suitably from about 5cm to about 50cm, preferably about 25cm.
• the process is suitably carried out at temperatures from about 5 0 C to about 45 0 C, preferably about 25 0 C to about 35 0 C, and at elevated pressures e.g. from about 80 bar to 300 bar, preferably about 100 bar to 150 bar.
• Typical flow rates depend upon the diameter of the column and may vary from e.g. lmL/min to about 5kg/m ⁇ n.
• the present invention provides a prostaglandin obtainable by a method as described above.
• o Eluent Carbon Dioxide (CO 2 ) with an alcoholic Co-solvent modifier (specifically
• Latanoprost Collection Collect the Latanoprost peak (heart cut) from approximately 30 seconds after peak start the baseline from the detected LatanoprOSt peak front (at ⁇ 410 seconds in retention time) to approximately 30 seconds prior to the peak end (at ⁇ 510 seconds in retention time).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Furan Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (2)

Family

ID=43126874

Family Applications (1)

Country Status (3)

Cited By (8)

Families Citing this family (13)

Family Cites Families (11)

• 2010
  • 2010-06-22 JP JP2012517644A patent/JP6087147B2/ja not_active Expired - Fee Related
  • 2010-06-22 US US12/820,610 patent/US8519178B2/en not_active Expired - Fee Related
  • 2010-06-22 WO PCT/US2010/039457 patent/WO2011005505A2/en not_active Ceased
• 2013
  • 2013-07-29 US US13/953,236 patent/US8957240B2/en active Active
• 2015
  • 2015-01-12 US US14/594,668 patent/US9353055B2/en active Active
• 2016
  • 2016-11-16 JP JP2016223583A patent/JP6633497B2/ja not_active Expired - Fee Related
• 2018
  • 2018-01-18 JP JP2018006190A patent/JP2018104435A/ja active Pending
• 2019
  • 2019-12-26 JP JP2019235482A patent/JP2020090500A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events